ADVFN Logo

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

PTN Palatin Technologies Inc New

1,84
0,24 (15,00%)
29 Mar 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Palatin Technologies Inc New PTN AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,24 15,00% 1,84 00:50:50
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,61 1,61 1,92 1,87 1,60
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/3/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202418:57EDGAR2Form 144 - Report of proposed sale of securities
28/2/202413:30PRNUSPalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3..
15/2/202415:00EDGAR2Form 8-K - Current report
15/2/202413:30PRNUSPalatin Reports Second Quarter Fiscal Year 2024 Financial..
14/2/202422:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/2/202420:55EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202413:30PRNUSPalatin to Report Second Quarter Fiscal Year 2024 Results;..
05/2/202413:30PRNUSPalatin Announces Database Lock for PL9643 MELODY-1 Pivotal..
01/2/202423:16EDGAR2Form 8-K - Current report
01/2/202422:00PRNUSPalatin Announces Closing of $10 Million Registered Direct..
30/1/202414:00PRNUSPalatin Announces $10 Million Registered Direct Offering
08/1/202416:33PRNUSPalatin Provides Corporate Update and Highlights Strategic..
03/1/202414:00BWCosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide..
20/12/202315:00EDGAR2Form 8-K - Current report
20/12/202313:30PRNUSPalatin Completes Sale of Vyleesi® to Cosette..
18/12/202322:45EDGAR2Form 8-K - Current report
18/12/202322:15PRNUSPalatin Receives Notice of Acceptance of the Listing..
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
08/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202323:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202320:25EDGAR2Form 144 - Report of proposed sale of securities
04/12/202323:00EDGAR2Form S-1 - General form for registration of securities under..
01/12/202321:52EDGAR2Form 144 - Report of proposed sale of securities
14/11/202313:30PRNUSPalatin Reports First Quarter Fiscal Year 2024 Financial..
09/11/202313:30PRNUSPalatin to Report First Quarter Fiscal Year 2024 Results;..
24/10/202322:50PRNUSPalatin Announces Closing of $5 Million Registered Direct..
24/10/202322:05EDGAR2Form 8-K - Current report
23/10/202313:30PRNUSPalatin Announces $5 Million Registered Direct Offering
19/10/202314:01EDGAR2Form 8-K - Current report
19/10/202313:30PRNUSPalatin Announces Preliminary Quarter Ended September 30,..
18/10/202313:30PRNUSPalatin Announces Positive Preclinical Data Showing..
16/10/202313:30PRNUSPalatin Presents Data at the United European..
13/10/202322:31EDGAR2Form 8-K - Current report
13/10/202322:15PRNUSPalatin Receives Notice of Non-Compliance from NYSE American
28/9/202314:02EDGAR2Form 8-K - Current report
28/9/202314:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
28/9/202313:30PRNUSPalatin Reports Fourth Quarter and Fiscal Year Ended 2023..
22/9/202322:00PRNUSPalatin to Report Fourth Quarter and Fiscal Year End 2023..
08/9/202314:00EDGAR2Form 8-K - Current report
07/9/202322:00PRNUSPalatin to Present at the H.C. Wainwright 25th Annual Global..
07/9/202314:49EDGAR2Form 8-K - Current report
07/9/202313:30PRNUSPalatin Completes Enrollment in Phase 3 MELODY-1 Study of..
17/8/202303:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202314:15EDGAR2Form 8-K - Current report
10/8/202313:30PRNUSPalatin Initiates Clinical Program for Bremelanotide..
08/8/202314:00EDGAR2Form 8-K - Current report
08/8/202313:30PRNUSPalatin's Vyleesi® Licensee Fosun Pharma Reports First..
07/8/202314:00EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

Delayed Upgrade Clock